Table 3.
Metastatic response after TVD stratified by metastatic response after COJEC
| Metastatic response after COJEC | Metastatic response after TVD |
||||||
|---|---|---|---|---|---|---|---|
| CR | PR ≤ 3 mIBG spots and negative bone marrow | PR > 3 mIBG spots and negative bone marrow | MR | SD | PD | ||
| PR | 46 (73.0) | 14 (30.4) | 6 (13.0) | 9 (21.7) | 10 (21.7) | 7 (15.2) | 0 |
| SD | 16 (25.4) | 3 (18.8) | 0 | 0 | 6 (37.5) | 7 (43.7) | 0 |
| PD | 1 (1.6) | 0 | 0 | 0 | 0 | 0 | 1 (100) |
| Total | 63 | 17 (27.0) | 6 (9.5) | 9 (14.3) | 16 (25.4) | 14 (22.2) | 1 (1.6) |
Values are presented as number (%). Eligibility to HDT: p=0.059 (chi-square test) comparing patients with PR after COJEC vs. those with < PR. TVD, topotecan-vincristine-doxorubicin; CR, complete response; PR, partial response; mIBG, metaiodobenzylguanidine; MR, mixed response; SD, stable disease; PD, progressive disease.